DC Chemicals Limited
China
Product Name: N-Desmethyltamoxifen
Price:
Purity: 98.0%
Stocking Period: 3 Day
Contact: Tony Cao

31750-48-8

31750-48-8 structure

Name: N-Desmethyltamoxifen
Chemical Name: n-desmethyltamoxifen, hydrochloride
CAS Number: 31750-48-8
Molecular Formula: C₂₅H₂₇NO
Molecular Weight: 357.48800
Catalog: Signaling Pathways Epigenetics PKC
Create Date: 2016-10-02 20:42:21
Modify Date: 2024-01-31 18:51:47
N-Desmethyltamoxifen is the major metabolite of tamoxifen in humans. N-Desmethyltamoxifen, a poor antiestrogen, is a ten-fold more potent protein kinase C (PKC) inhibitor than Tamoxifen. N-Desmethyltamoxifen is also a potent regulator of ceramide metabolism in human AML cells, limiting ceramide glycosylation, hydrolysis, and sphingosine phosphorylation[1][2][3].

Name	n-desmethyltamoxifen, hydrochloride
Synonyms	desmethyl Tamoxifen N-Desmethyl-psilocybin N-demethyltamoxifen N-desmethyl-tamoxifen Baeocystin

Description	N-Desmethyltamoxifen is the major metabolite of tamoxifen in humans. N-Desmethyltamoxifen, a poor antiestrogen, is a ten-fold more potent protein kinase C (PKC) inhibitor than Tamoxifen. N-Desmethyltamoxifen is also a potent regulator of ceramide metabolism in human AML cells, limiting ceramide glycosylation, hydrolysis, and sphingosine phosphorylation[1][2][3].
Related Catalog	Signaling Pathways >> Others >> Estrogen Receptor/ERR Signaling Pathways >> Epigenetics >> PKC Research Areas >> Cancer Signaling Pathways >> TGF-beta/Smad >> PKC
Target	PKC
In Vitro	N-desmethyltamoxifen (20-500 ng/ml; 48 hours) has a profound inhibitory effect upon all seven glioma lines (T98G, U87, U138, U373, ALW, AUK, CAS cells)[1]. N-desmethyltamoxifen (1.5-10 μM; 114 hours) inhibits growth of MCF 7 human mammary carcinoma cells[2]. N-desmethyltamoxifen, resulting from the CYP3A4/5-mediated catalysis of tamoxifen, is the major primary quantitative metabolite of tamoxifen[3]. Cell Viability Assay[2] Cell Line: MCF 7 human mammary carcinoma cells Concentration: 1.5, 2.5, 5, 7.5, 10 μM Incubation Time: 114 hours Result: Inhibits growth of MCF 7 human mammary carcinoma cells
References	[1]. Vertosick FT Jr, et al. A comparison of the relative chemosensitivity of human gliomas to tamoxifen and n-desmethyltamoxifen in vitro. J Neurooncol. 1994;19(2):97-103. [2]. Morad SA, et al. Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia--Impact on enzyme activity and response to cytotoxics. Biochim Biophys Acta. 2015 Jul;1851(7):919-28. [3]. Reddel RR,et al. N-desmethyltamoxifen inhibits growth of MCF 7 human mammary carcinoma cells in vitro. Eur J Cancer Clin Oncol. 1983 Aug;19(8):1179-81. [4]. Seong Hwan Kim,et al. Use of Antidepressants in Patients with Breast Cancer Taking Tamoxifen. J Breast Cancer. 2010 Dec;13(4):325-336.

Density	1.047 g/cm3
Boiling Point	485.8ºC at 760 mmHg
Molecular Formula	C₂₅H₂₇NO
Molecular Weight	357.48800
Flash Point	213.2ºC
Exact Mass	357.20900
PSA	21.26000
LogP	6.04480

CHEMICAL IDENTIFICATION

RTECS NUMBER :: KR6712700

CHEMICAL NAME :: Ethylamine, 2-(p-(1,2-diphenyl-1-butenyl)phenoxy)-N-methyl-, (Z)-

CAS REGISTRY NUMBER :: 31750-48-8

LAST UPDATED :: 198910

DATA ITEMS CITED :: 1

MOLECULAR FORMULA :: C25-H27-N-O

MOLECULAR WEIGHT :: 357.53

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 50 ug/kg

SEX/DURATION :: female 4 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea)

REFERENCE :: CTRRDO Cancer Treatment Reports. (Washington, DC) V.60-71, 1976-87. For publisher information, see JNCIEQ. Volume(issue)/page/year: 64,741,1980

Hazard Codes	Xn

31750-48-8	31750-47-7
112093-28-4	110025-28-0
15917-65-4	158729-32-9
58068-80-7	13402-08-9
10162-76-2	21248-24-8